Immunotherapy for clinically isolated syndrome? Not necessarily...
Aksel Siva
Correspondence Department of Neurology, Istanbul University Cerrahpa
a School of Medicine Cerrahpaa, 34098 Istanbul, Turkey
Email asiva@turk.net
Multiple sclerosis (MS) is a complex disease with a high degree of clinical and neuropathological variability between patients. In this Viewpoint, Aksel Siva argues that such a heterogeneous disease demands a heterogeneous approach to treatment and questions the practice of initiating long-term immunotherapy before the MS diagnosis has become definite.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.